Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generics Bulletin’s Top 50 Ranking For 2021

Compiling All The Data From Our List Of The Top Industry Players

Executive Summary

This article brings you a compilation of all the data from Generics Bulletin’s recent ranking of the top 50 generics and biosimilars companies, including additional details of how the financial figures stack up.

You may also be interested in...



Generics Bulletin Editor’s Picks For Q3 2021

Looking back over a busy third quarter in 2021, Generics Bulletin executive editor David Wallace picks out highlights from July to September that include major legal and regulatory developments, multiple firsts in the biosimilars arena, significant M&A activity and our annual ranking of the off-patent sector’s top 50 companies.

Lupin Expects Exeltis Partnership To Boost Solosec

Lupin is hoping that a newly-struck partnership with women’s health specialist Exeltis will improve the fortunes of its Solosec (secnidazole) bacterial vaginosis and trichomoniasis treatment in the US.

Biogen Sells Samsung Bioepis Stake In $2.3bn Buyout

Biogen has struck a deal that will see it sell its equity stake in the Samsung Bioepis biosimilars joint venture to partner Samsung Biologics for up to $2.3bn.

Topics

UsernamePublicRestriction

Register

GB151150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel